29–33%
of men 65+ affected by BPH
NIDDK / NIH
The three gates
Three checks decide a BPH-device claim before anyone reads the op note.
Across major commercial policies, minimally invasive surgical therapy (MIST) for BPH is gated on the same three findings. Aetna’s clinical policy bulletin is representative: UroLift is covered for a prostate roughly 30–80 g without an obstructive median lobe; iTind for 25–75 g, again without median-lobe obstruction; and Rezum is still flagged experimental by some plans despite FDA clearance.1
Prostate size
The covered window
Volume outside the covered window — or simply not documented in cc/g.
Median lobe
Obstructive anatomy
An obstructive median lobe is present — or its absence is never stated in the chart.
Medical therapy first
The ladder, on paper
No documented trial or failure of an alpha-blocker ± a 5-ARI before MIST.
None of these is a judgment on the surgery. They’re documentation gates — and a denial at any one of them is appealable the moment the chart speaks the policy’s language. That is exactly the pattern our urology denial work is built to answer.
The ladder
Payers want to see the AUA ladder climbed — on paper.
The AUA guideline on LUTS attributed to BPH frames intervention as a step after medical management: offer an alpha blocker as first-line therapy; add a 5-alpha-reductase inhibitor when the prostate is documented as enlarged; combination therapy is appropriate; surgical and minimally invasive therapy is generally for moderate-to-severe LUTS when medical therapy fails or isn’t tolerated.2 The denial reason “conservative therapy not tried” almost always means a lower rung wasn’t recorded.
01
Behavioral / watchful waiting
02
Alpha blocker
03
5-ARI (if enlarged)
04
Combination therapy
05
MIST — UroLift / iTind / Rezum
AUA recommendations are directional; payers translate them into prerequisite documentation. The appeal’s job is to show each required rung was met or appropriately skipped.
Label vs policy
The median-lobe gap: FDA-cleared, payer-denied.
In June 2020 the FDA cleared UroLift for obstruction due to BPH including lateral and median lobe hyperplasia, in men aged 45 and older.3 Yet many payer policies still require the absence of an obstructive median lobe for coverage.1 That is the same shape of gap that defines device denials across specialties: the label moved, the policy didn’t — and the difference is recoverable on appeal. It’s the kind of mismatch that surfaces when you look at what reviewers actually read.
On Medicare coverage
There is no active Medicare LCD specific to prostatic urethral lift. Coverage rides on medical necessity and documentation — which means the chart, not the catheter, decides the claim.
With no PUL-specific national or local coverage determination, UroLift is paid case-by-case on documented medical necessity.4 That cuts both ways: there’s no blanket policy to lean on, so a well-built record is the entire argument — and a thin one is the entire denial.
Coding alert
The 2025 iTind change that quietly creates denials.
Effective January 1, 2025, CMS retired iTind’s Category III billing and established two Category I CPT codes. Practices still billing the old way invite a clean-claim rejection that looks like a coverage denial but is really a coding one.5
iTind — current coding
Category III is retired. Use the Category I pair.
0714T (legacy)
53865 — insertion
53866 — removal
For reference, UroLift remains 52441 (single implant) + 52442 (each additional, add-on); the facility side uses C9739 (1–3 implants) / C9740 (4+). 52442 must accompany 52441, with documented implant counts.
The math
An aging-male population, and denials no one appeals.
BPH affects 29–33% of men aged 65 and older (and 5–6% of men 40–64) — the most common prostate problem in men over 50.6 The demand is structural and growing. Yet the appeals behavior is the same as everywhere else in medicine: across Medicare Advantage in 2024, only 11.5% of denials were appealed, while 80.7% of those appeals were overturned.7 For a procedure billed in the low thousands, an un-appealed denial is pure leakage.
11.5%
of MA denials appealed, 2024
KFF · 2024
80.7%
of those appeals overturned
KFF · 2024
The demand is structural; the leakage is a habit. When four in five appealed MA denials reverse but only one
in nine is ever filed, the win isn’t fighting harder on the appeals you already send — it’s
making each one cheap enough to file all of them.
The move
Answer all three gates — in minutes, not after-hours.
Merits turns a BPH-device denial into a ready-to-send, payer-specific appeal: it answers the exact denial reason, pulls the documented prostate volume, the median-lobe finding, and the medical-therapy history into the rebuttal, and cites the governing policy or the FDA clearance where the policy lags — every clinical detail verified verbatim against the chart. Your team reviews and signs. The letter never mentions Merits or AI; the provider files it under their own name.